HP
LGND icon

HealthInvest Partners’s Ligand Pharmaceuticals LGND Stock Holding History

HealthInvest Partners’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$2.77M Sell
32,381
-44,403
-58% -$3.85M 5.84% 8
2017
Q3 		$6.52M Sell
76,784
-13,305
-15% -$1.05M 7.62% 6
2017
Q2 		$6.82M Buy
+90,089
New +$6.3M 8.51% 8

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

HealthInvest Partners's LGND Position: Q4 2017 in Review

HealthInvest Partners reduced its Ligand Pharmaceuticals (LGND) stake by 58% in Q4 2017, selling an estimated $3.85M and leaving 32,381 shares worth $2.77M. The position accounts for 5.84% of the portfolio, ranked #8.

HealthInvest Partners first reported a position in LGND in Q2 2017 and has held it in 3 quarters since. The position peaked at $6.82M in Q2 2017. 298 funds tracked by Wall St. Rank hold LGND as of Q4 2017.

  • HealthInvest Partners held 32,381 shares of Ligand Pharmaceuticals worth $2.77M as of Q4 2017.
  • HealthInvest Partners sold 44,403 Ligand Pharmaceuticals shares in Q4 2017, an estimated $3.85M.
  • Ligand Pharmaceuticals made up 5.84% of HealthInvest Partners's portfolio in Q4 2017, its #8 holding.
  • HealthInvest Partners first reported a position in Ligand Pharmaceuticals in Q2 2017 and has held it in 3 quarters since.
  • HealthInvest Partners's Ligand Pharmaceuticals position peaked at $6.82M in Q2 2017.
  • 298 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2017.

Based on HealthInvest Partners's 13F filing for Q4 2017, filed 9 Feb 2018.